Brokers Set Expectations for Neurocrine Biosciences, Inc.’s Q1 2025 Earnings (NASDAQ:NBIX)

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Equities research analysts at William Blair issued their Q1 2025 earnings per share estimates for shares of Neurocrine Biosciences in a research report issued to clients and investors on Tuesday, April 23rd. William Blair analyst M. Minter anticipates that the company will post earnings of $1.28 per share for the quarter. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $4.84 per share. William Blair also issued estimates for Neurocrine Biosciences’ Q2 2025 earnings at $1.56 EPS, Q3 2025 earnings at $1.75 EPS and Q4 2025 earnings at $1.99 EPS.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Wednesday, February 7th. The company reported $1.44 earnings per share for the quarter, beating analysts’ consensus estimates of $1.13 by $0.31. The firm had revenue of $515.20 million during the quarter, compared to analysts’ expectations of $518.52 million. Neurocrine Biosciences had a net margin of 13.23% and a return on equity of 12.85%. The business’s quarterly revenue was up 25.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.88 earnings per share.

Other research analysts have also issued reports about the company. StockNews.com upgraded Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 8th. Wedbush reiterated an “outperform” rating and issued a $147.00 price objective on shares of Neurocrine Biosciences in a research note on Wednesday, April 17th. Citigroup cut their target price on shares of Neurocrine Biosciences from $141.00 to $140.00 and set a “neutral” rating on the stock in a research note on Thursday, February 8th. HC Wainwright reaffirmed a “buy” rating and issued a $150.00 target price on shares of Neurocrine Biosciences in a report on Wednesday. Finally, JPMorgan Chase & Co. boosted their price target on shares of Neurocrine Biosciences from $148.00 to $158.00 and gave the stock an “overweight” rating in a report on Wednesday, March 20th. Six investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $142.38.

Neurocrine Biosciences Stock Down 0.9 %

Shares of NBIX stock opened at $137.76 on Thursday. Neurocrine Biosciences has a 52 week low of $89.04 and a 52 week high of $148.37. The firm has a 50 day moving average of $136.56 and a two-hundred day moving average of $127.69. The stock has a market capitalization of $13.71 billion, a PE ratio of 56.93 and a beta of 0.25.

Hedge Funds Weigh In On Neurocrine Biosciences

Institutional investors have recently added to or reduced their stakes in the stock. Vestal Point Capital LP acquired a new stake in Neurocrine Biosciences during the 4th quarter worth approximately $105,408,000. Los Angeles Capital Management LLC raised its stake in shares of Neurocrine Biosciences by 66.0% during the fourth quarter. Los Angeles Capital Management LLC now owns 918,391 shares of the company’s stock worth $121,007,000 after purchasing an additional 364,986 shares during the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of Neurocrine Biosciences by 120.6% during the third quarter. Assenagon Asset Management S.A. now owns 584,539 shares of the company’s stock worth $65,761,000 after purchasing an additional 319,564 shares during the period. Westfield Capital Management Co. LP lifted its holdings in shares of Neurocrine Biosciences by 73.0% during the third quarter. Westfield Capital Management Co. LP now owns 649,292 shares of the company’s stock worth $73,045,000 after purchasing an additional 273,952 shares during the period. Finally, Norges Bank purchased a new position in Neurocrine Biosciences in the 4th quarter valued at $35,731,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Eiry Roberts sold 1,457 shares of Neurocrine Biosciences stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $140.79, for a total transaction of $205,131.03. Following the transaction, the insider now owns 20,832 shares of the company’s stock, valued at $2,932,937.28. The transaction was disclosed in a filing with the SEC, which is available at this link. In related news, insider Eiry Roberts sold 1,457 shares of the stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $140.79, for a total transaction of $205,131.03. Following the completion of the sale, the insider now owns 20,832 shares in the company, valued at approximately $2,932,937.28. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Richard F. Pops sold 15,000 shares of the firm’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $132.47, for a total transaction of $1,987,050.00. Following the transaction, the director now directly owns 29,512 shares in the company, valued at $3,909,454.64. The disclosure for this sale can be found here. Insiders sold a total of 186,994 shares of company stock valued at $25,806,409 in the last three months. 4.40% of the stock is currently owned by company insiders.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.